1. Home
  2. BMY vs SNPS Comparison

BMY vs SNPS Comparison

Compare BMY & SNPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bristol-Myers Squibb Company

BMY

Bristol-Myers Squibb Company

N/A

Current Price

$60.67

Market Cap

127.0B

Sector

Health Care

ML Signal

N/A

Logo Synopsys Inc.

SNPS

Synopsys Inc.

N/A

Current Price

$433.75

Market Cap

90.9B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
BMY
SNPS
Founded
1887
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
127.0B
90.9B
IPO Year
2006
1994

Fundamental Metrics

Financial Performance
Metric
BMY
SNPS
Price
$60.67
$433.75
Analyst Decision
Hold
Strong Buy
Analyst Count
28
25
Target Price
$65.25
★ $589.55
AVG Volume (30 Days)
★ 9.2M
1.7M
Earning Date
10-29-2026
12-08-2026
Dividend Yield
★ 4.11%
N/A
EPS Growth
★ 178.46
N/A
EPS
★ 3.98
3.27
Revenue
★ $48,194,000,000.00
$5,081,542,000.00
Revenue This Year
$4.23
$37.81
Revenue Next Year
N/A
$13.18
P/E Ratio
★ $15.42
$133.21
Revenue Growth
N/A
★ 20.87
52 Week Low
$45.27
$362.55
52 Week High
$68.64
$539.48

Technical Indicators

Market Signals
Indicator
BMY
SNPS
Relative Strength Index (RSI) 43.05 43.03
Support Level $59.94 $403.46
Resistance Level $60.93 $444.66
Average True Range (ATR) 1.67 15.53
MACD -0.15 -3.66
Stochastic Oscillator 1.05 17.31

Price Performance

Historical Comparison
BMY
SNPS

About BMY Bristol-Myers Squibb Company

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

About SNPS Synopsys Inc.

Synopsys is a provider of electronic design automation software and intellectual property products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Synopsys' comprehensive portfolio is benefiting from a convergence of semiconductor companies moving up the stack of technologies toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

Share on Social Networks: